X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED), the most common form of ectodermal dysplasia, is caused by a broad spectrum of mutations in the ectodysplasin A1 (EDA-A1) gene. The main symp- toms of XLHED are hypo- or anhidrosis, oligo- or anodontia and hypotrichosis. Current treatment options are limited to managing disease symptoms and complications. Effective corrective treatment for XLHED remains a high unmet medical need.
Edelife is a clinical study of the safety and possible health benefits of an investigational medicine for pregnant women expecting an ectodermal dysplasia (XLHED) affected boy.
The Edelife investigational treatment, ER004, consists of a first-in-class signaling protein replace- ment molecule designed for specific, high affinity binding to the endogenous receptor, intended to replace missing EDA-A1 protein in utero for patients with XLHED.
Administration at several specific points in pregnancy is essential, as ER004 impacts development of ectodermal precursors of sweat glands, teeth, etc.
Positive Outcomes in Compassionate Use of ER004 in XLHED Patients
Early referral is essential, as screening for Edelife must occur between weeks 19-24 of pregnancy. Contact an Edelife clinical site to refer a patient or request more information.
This is a website about the Edelife Clinical Trial dedicated to Healthcare Professionals.
This information is presented only for providing overview information about a clinical trial with an investigational product. It should not be construed as a recommendation for an unapproved use.
I certify that I am a Healthcare Professional and I have read the information above:
This is a website about the Edelife Clinical Trial dedicated to Healthcare Professionals.